The DAPT Study was an independent, large-scale study in size and scope intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication to reduce the risk of blood clots) to protect patients from stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE) following the implantation of drug-eluting coronary stents.
The DAPT Study was an international initiative that was developed by a group of eight manufacturers (four major stent manufacturers and four manufacturers of antiplatelet medications) who came together to address a U.S. Food and Drug Administration (FDA) request for this post-market study. The Harvard Clinical Research Institute (www.hcri.harvard.edu) was responsible for the scientific conduct and independent analysis of the overall study.
Final results from the DAPT Study were released on November 16, 2014 at the American Heart Association Scientific Sessions. Click here for more information on the results.